Hopes for an effective vaccine against the novel coronavirus have been boosted by positive Phase I/II data from the BNT162 mRNA-based vaccine program.
Germany’s BioNTech SE (Nasdaq: BNTX) is working with New York-based Pfizer (NYSE: PFE) to develop four investigational vaccine candidates. The project includes a mass manufacturing program which could deliver over a billion doses by the end of 2021.
The preliminary data demonstrated that the most advanced of the four candidates, BNT162b1, could be administered in a dose that was well tolerated and which generated dose-dependent immunogenicity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze